IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia

October 4, 2017

The randomized, double blind and placebo controlled study with the drug candidate IRL752 has been initiated with the first dosing. The study aims to provide information on the safety, tolerability and efficacy of IRL752 in patients with Parkinson’s disease dementia. Today, there is a lack of effective treatment options for these patients and thus, the medical needs are large. The study, which is carried out in Scandinavia, is planned to recruit about 40 patients and a have a treatment duration of four weeks. The study is estimated to be concluded during the second quarter of 2018.

For full press release, click here for English version and click here for Swedish version.